Nasal spray showed positive results in treating the C-19 v=virus. It is affordable without a prescription.
Join Our Telegram channel here: https://t.me/TheTrueReporter
If this sounds ok to you, then you won’t be shocked to hear that the U.S. federal government wants to ban nasal spray. All the things that function against the virus are forbidden, so the vaccines would remain the only ‘’solution’’ people will have.
The leading US manufacturer of Xylitol-based products says the US federal government is deliberately trying to conceal a nasal spray it developed that it says has been scientifically proven to be effective in treating and preventing #COVID19. https://t.co/NLLIQFKSUB
— The Epoch Times (@EpochTimes) November 11, 2021
— ᚷᚱᛁᛗᚾᛁᚱ ʕ´•ᴥ•`ʔ #DestroyTheAadhaar (@CryoPerSea) November 12, 2021
COVID-19 is the disease caused by SARS-CoV-2, commonly known as the novel coronavirus.https://t.co/NIyMuYkTHb
— Collective Spark (@CollectiveSprk) November 12, 2021
Of course they want to block it how could someone even suggest a therapeutic approach to C-19? Vaccine or bust…
Feds Seek to Block Promotion of a Nasal Spray Against COVID-19 https://t.co/tdcfYHBFfk
— Lem Taylor (@LemTaylor_PhD) November 12, 2021
We are going to talk about the nasal spray – Xlear.
What is Xlear?
It represents a natural saline spray that helps relieve congestion. The spray will clean the nostrils and prevent bacteria and other toxins from sticking to the nasal tissues.
The formula added xylitol to clean and moisturize the inside part of the nose so that the nasal passages wouldn’t face dryness.
Xlear’s crucial ingredients are saline, grapefruit seed extracts, and xylitol, and that’s a plant-derived sweetener used in oral care products.
The Utah-based company stated that nasal spray effectively treats and prevents the coronavirus.
But, now the government will ban this drug because the officials are annoyed when something else is being promoted rather than the vaccine.
The U.S. Department of Justice filed a lawsuit in federal court against Utah-based company Xlear on Oct. 28, saying it has deceptively advertised its nasal spray as a treatment and preventative of COVID-19.
The lawsuit asks a federal court to permanently ban the company from promoting the nasal spray as a treatment for COVID-19 and also asks that monetary penalties be levied against it.
COVID-19 is the disease caused by SARS-CoV-2, commonly known as the novel coronavirus.
The DOJ filed the complaint on behalf of the Federal Trade Commission, which alleges the company has violated the Federal Trade Commission Act and the Consumer Protection Act by making false claims about the benefits.
“Companies can’t make unsupported health claims, no matter what form a product takes, or what it supposedly prevents or treats,” said Samuel Levine, director of the trade commission’s Bureau of Consumer Protection, said in a press release on the lawsuit.
“That’s the lesson of this case and many others like it, and it’s why people should continue to rely on medical professionals over ads.”
Housman pointed out that the National Institute of Allergy and Infectious Diseases (NIAID)—along with the National Institutes of Health (NIH), an arm of the Department of Health and Human Services—funded clinical studies of the use of nasal sprays like Xlear’s and published findings last year that found they were an effective treatment and method of prevention for COVID-19.
“When Xlear tells people about scientific studies, even ones republished by the NIH, we are somehow misleading people and making false claims. It’s nonsensical,” Housman told The Epoch Times.
“Rather than embrace nasal interventions, the government is trying to eliminate their use because they don’t fit the government’s highly flawed, vaccine-only agenda.”
The N.I supported one study that reached the nasal spray’s effectiveness against C-19.
The clinical trial took place at the Vanderbilt University Medical Center in Tennessee and investigated nasal saline irrigations to treat the virus.
September 2020 study stated:
Nasal saline irrigation is a commonly accepted and inexpensive therapy with proven efficacy as a treatment for viral upper respiratory infections and has been proposed as a potentially beneficial treatment for COVID-19.9 Here, we present initial findings from the first RCT evaluating nasal irrigations in non-hospitalized patients with COVID-19. The effect of nasal irrigation on symptom resolution was substantial, with nasal congestion and headache resolving a median of 7 to 9 days earlier in the intervention groups. Our analysis suggests that nasal irrigations may shorten symptom duration and may have potential as a widely available and inexpensive intervention to reduce disease burden among those affected. The additive effects of surfactant remain unclear, because the impact of HTS and HTSS on symptom resolution was fairly equivalent, and it has been reported that surfactant nasal irrigations are associated with some tolerability issues in a subset of patients.10 However, the addition of surfactant may have beneficial effects on viral shedding and/or maturation given their reported ability to rapidly induce membrane dissolution and lysis of many viruses and other microorganisms.
After the results showed positive treatment of the curs, an additional study was conducted in November 2020.
During the early stages of COVID-19, could a commercially available nasal spray containing xylitol and grapefruit seed extract (GSE), namely Xlear Nasal Spray be beneficial? https://t.co/a8QIg3wxyF
— Linda Mulvey (@LindaMulvey4) November 12, 2021
XLEAR NASAL SPRAY COVID-19: STUDY CONCLUDES XLEAR KILLS AND/OR DEACTIVATES SARS-COV-2; EFFICACY AGAINST NEW VARIANTShttps://t.co/swpgq1eNsk
— TΞJAS (@tejasreports) November 11, 2021
At Larkin Community Hospital in Florida, the study was performed stating that the spray eased symptoms in half the time.
Collective Spark reported:
The Justice Department didn’t specifically cite the Larkin, Vanderbilt, or Augusta trials in its lawsuit.
It instead cited the results of lab studies conducted earlier at the University of North Carolina–Chapel Hill and the University of Tennessee involving in vitro and animal testing, neither of which the DOJ and FTC argue is a viable way to test nasal spray for live, human COVID-19 patients.
The lawsuit additionally pointed out that the University of Tennessee study is based on a nasal spray containing iota-carrageenan, which the Xlear spray does not contain and, therefore, cannot be used as scientific evidence to support Xlear’s claims.
The lawsuit also stated that researchers at Chapel Hill admitted that without further research it couldn’t conclusively determine that “administering treatment through the nose is the best way to treat COVID-19.”
Housman said the trade commission cherry-picked findings within the lab studies to make them fit its agenda.
The federal government has warned companies against promoting nasal sprays for the treatment and prevention of COVID-19.
BlueWillow Biologics, a Michigan biopharmaceutical company that manufactures a nasal antiseptic, and the Miami-based company Halodine, which created a proprietary iodine-based nasal antiseptic swab, both received warning letters earlier this year from the FDA to discontinue their promotion of their nasal products as a safe and effective treatment for COVID-19.
Join Our Telegram channel here: https://t.me/TheTrueReporter